Insta
Human Trials Of India's First Covid-19 Vaccine Begin; 375 Volunteers To Participate In Phase-1 Trial
COVAXIN, India’s first indigenous vaccine against Coronavirus. (Swarajya Magazine)
In a significant development, the Phase-I human clinical trials of India's first indigenous COVID-19 vaccine candidate has taken off at various centres across the country with 375 volunteers slated to be enrolled for the first phase, reports Indian Express.
Developed by Hyderabad based Bharat Biotech in collaboration with Pune based National Institute of Virology (NIV) and the Indian Council of Medical Research (ICMR), the potential Covid-19 vaccine has been named 'Covaxin'.
The successful completion of the Phase-I trial will be followed by a Phase-II trial, and both the phases will involve a total of 1,125 volunteers who will be administered the vaccine. The Phase-I trial has begun at AIIMS, Patna.
Meanwhile, it should be noted that apart from Covaxin developed by Bharat Biotech, another Indian pharmaceutical major Zydus Cadila has also developed a potential vaccine, ZyCoV-D, which has also begun the human clinical trials.
The development of two potential vaccines has placed India among a select group of nations which have been able to make such strides in developing a vaccine for the COVID-19 disease which has wreaked havoc across the globe.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
